<DOC>
	<DOCNO>NCT01696461</DOCNO>
	<brief_summary>This Phase II , open-label , two stratum , multicenter , prospective study plerixafor-mobilized HLA-identical sibling allograft recipient hematological malignancy . This study establish safety efficacy subcutaneous plerixafor purpose .</brief_summary>
	<brief_title>A Phase II Study Evaluating Safety Efficacy Subcutaneous Plerixafor</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Donor : Donor eligibility determine accord applicable federal , state local regulation institutional standard 1865 year age 6/6 HLAmatched sibling Fulfill individual Transplant Center criterion serve mobilize blood cell donor Serum creatinine &lt; 2.0mg/dl Recipient : 18 65 year age 6/6 HLA antigen match sibling willing donate PBSC transplant Fulfill individual Transplant Center Criteria transplant One follow diagnosis : Acute myelogenous leukemia ( AML ) 1st remission beyond &lt; 5 % marrow blast circulate blast . Marrow must do within 30 day start transplant conditioning regimen alignment pretransplant assessment . Acute lymphoblastic leukemia ( ALL ) 1st remission beyond &lt; 5 % marrow blast circulate blast Myelodysplastic syndrome , either intermediate1,2 , high risk International Prognostic Scoring System transfusion dependent Chronic myelogenous leukemia ( CML ) fail intolerant tyrosine kinase inhibitor base therapy NonHodgkin 's lymphoma ( NHL ) Hodgkin 's disease ( HD ) 2nd great complete remission , partial remission , relapse ( least stable disease recent therapy ) Chronic lymphocytic leukemia ( CLL ) , relapse least one prior regimen , remission 17p deletion Serum creatinine must &lt; 2.0mg/dl Total bilirubin AST &lt; 3x normal Infectious disease marker ( IDM ) monitoring perform per institutional standard Karnofsky performance status 70 % great . Patients undergone prior autologous transplantation eligible reduce intensity transplant Donor : Donor unwilling unable give inform consent , unable comply protocol include require followup test Donor already enrol another investigational agent study Pregnant breast feeding female , female willing able use adequate contraception sexually active Recipient : Patient unwilling unable give inform consent , unable comply protocol include require followup test Patients active , uncontrolled infection time transplant preparative regimen Pregnant breast feeding female , female willing able use adequate contraception sexually active Patients history previous CNS tumor involvement show active symptom sign along document disease lumbar puncture MRI brain within 30 day start condition A condition , , opinion clinical investigator , would interfere evaluation primary secondary endpoint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>